Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
Author:
Affiliation:
1. Translational Development and Clinical Pharmacology Celgene Corporation Summit New Jersey
2. Biostatistics Celgene Corporation SummitNew Jersey
3. Non‐Clinical Development Celgene Corporation Summit New Jersey
Publisher
Wiley
Subject
General Pharmacology, Toxicology and Pharmaceutics,Neurology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.436
Reference31 articles.
1. Targeting the IDH2 Pathway in Acute Myeloid Leukemia
2. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation;DiNardo C;Clin Adv Hematol Oncol,2018
3. Enasidenib for the treatment of acute myeloid leukemia
4. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
5. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome;The Journal of Clinical Pharmacology;2024-04-02
2. Integrating Full Bayesian Inference and Student's t‐Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug–Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients;The Journal of Clinical Pharmacology;2024-03-13
3. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2 ‐Mutant Acute Myeloid Leukemia;Clinical Pharmacology in Drug Development;2022-02-14
4. Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome;The Journal of Clinical Pharmacology;2021-10-27
5. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study;Blood;2021-04-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3